The human proteome contains approximately 20,000 proteins, and it is estimated that more
than 600 of them are functionally important for various types of cancers, including nearly 400 …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

Enhancer of zeste homolog 2 (EZH2) is enzymatic catalytic subunit of polycomb repressive
complex 2 (PRC2) that can alter downstream target genes expression by trimethylation of …

Non-coding RNAs (ncRNAs) are a large family of RNA molecules with no capability in
encoding proteins. However, they participate in developmental and biological processes …

Canonically, EZH2 serves as the catalytic subunit of PRC2, which mediates H3K27me3
deposition and transcriptional repression. Here, we report that in acute leukaemias, EZH2 …

Prostate cancers are considered to be immunologically 'cold'tumors given the very few
patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of …

Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …

Cancer arises from a multitude of disorders resulting in loss of differentiation and a stem cell-
like phenotype characterized by uncontrolled growth. Polycomb Group (PcG) proteins are …

Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …

O-GlcNAc is a dynamic post-translational modification (PTM) that regulates protein functions.
In studying the regulatory roles of O-GlcNAc, a major roadblock is the inability to change O …